Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.49 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30498667 | 0.98 | CSNK2A1 (0.53) | CSNK2A1NOTUMASPHCES2DHODH | |
| SCHEMBL107636 | 0.86 | CSNK2A1 (0.52) | CSNK2A1NOTUMASPHCES2TAS2R14 | |
| SCHEMBL27827977 | 0.86 | CES2 (0.48) | CSNK2A1NOTUMCES2AKR1C3AKR1C2 | |
| SCHEMBL24405771 | 0.85 | CSNK2A1 (0.52) | CSNK2A1NOTUMTAS2R14GRIK1RXRA | |
| SCHEMBL18354210 | 0.85 | CES2 (0.47) | CSNK2A1NOTUMCES2AKR1C3AKR1C2 | |
| SCHEMBL12368663 | 0.83 | CES2 (0.46) | CSNK2A1NOTUMCES2DHODHAKR1C3 | |
| SCHEMBL16404629 | 0.83 | CES2 (0.46) | CSNK2A1NOTUMCES2AKR1C3AKR1C2 | |
| SCHEMBL4238024 | 0.82 | CSNK2A1 (0.57) | CSNK2A1NOTUMRXRBMEN1KMT2A | |
| SCHEMBL18159377 | 0.80 | CYP46A1 (0.53) | NOTUMCES2P2RX1TMPRSS4LMNA | |
| SCHEMBL13035850 | 0.80 | GAA (0.46) | CES2MEN1KMT2AALDH1A1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3294726-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9732066-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINY AKU CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2016168633-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-09-01 | — | — | US | disclosed |
| EP-2303871-B1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011050200-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| US-7923470-B2 | Benzooxazoles as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | KNUST HENNER | 2011-03-24 | — | — | US | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| CN-101903372-A | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN LA ROCHE | 2010-12-01 | — | — | CN | disclosed |
| EP-2234999-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | US | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | CASR, RYR1, RYR2 | CSNK2A1 1416/4885NOTUM 4444/4885ASPH 2609/4885 |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | CSNK2A1 2020/4885NOTUM 2631/4885ASPH 228/4885 |
| US-20110071154-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | CSNK2A1 1944/4885NOTUM 2339/4885ASPH 364/4885 |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | CSNK2A1 554/4885NOTUM 3434/4885ASPH 4231/4885 |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | CSNK2A1 554/4885NOTUM 3434/4885ASPH 4231/4885 |
| US-20100029664-A1 | PYRROLIDIN-3-YLMETHYL-AMINE AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | CSNK2A1 1944/4885NOTUM 2339/4885ASPH 364/4885 |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | TNF, CD40, TNFRSF1A | CSNK2A1 554/4885NOTUM 3434/4885ASPH 4231/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | CSNK2A1 703/4885NOTUM 4529/4885ASPH 2815/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | CSNK2A1 703/4885NOTUM 4529/4885ASPH 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.